Abstract
The neuroregulation of growth hormone (GH) secretion is mediated in part by a stimulatory, GH-releasing factor (GRF) and an inhibitory peptide, somatostatin1, both of which reach the adenohypophysis by the hypothalamic-hypophysial portal system2. Somatostatin has been shown to be a tetradecapeptide3,4, a large form of which was later also sequenced5. The existence of a GRF is supported by physiological evidence6–9 and by reports of GH-releasing activity in hypothalamic extracts10–17. Although several agents with GH-releasing activity have been identified14–16, none is of high potency and fulfils the criteria expected of a physiological GRF18,19. GH-releasing activity observed in extracts of carcinoid and pancreatic islet tumours removed from patients with GH hypersecretion, acromegaly and pituitary adenoma or hyperplasia has been partially characterized20–23. We report here the sequence of a 40 residue GH-releasing peptide purified from a pancreatic islet tumour described earlier by Thorner et al.23. A synthetic replicate of this peptide, termed human pancreatic tumour GRF [hpGRF(1–40)]-OH, co-elutes on HPLC with the native peptide and is highly potent in stimulating GH secretion in vitro and in vivo. A close structural homology with the peptides of the glucagon–secretin family, and more particularly with PHI24, is recognized. Structure–activity studies show that hpGRF(1–29)-NH2 has full intrinsic activity and potency in vitro.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Krulich, L., Dhariwal, A. P. S. & McCann, S. M. Endocrinology 83, 783–790 (1968).
Harris, G. W. Physiol. Rev. 28, 139–179 (1948).
Brazeau, P. et al. Science 179, 77–79 (1973).
Vale, W. et al. Rec. Prog. Hormone Res. 31, 365–397 (1975).
Pradayrol, L., Jörnvall, H., Mutt, V. & Ribet, A. FEBS Lett. 109, 55–58 (1980).
Bogdanove, E. M. & Lipner, H. J. Proc. Soc. exp. Biol. Med. 81, 410–412 (1952).
Frohman, L. A., Bernardis, L. L. & Kant, K. J. Science 162, 580–582 (1968).
Reichlin, S. Endocrinology 69, 225–230 (1961).
Martin, J. B. New Engl. J. Med. 288, 1386–1393 (1973).
Franz, J., Haselback, C. H. & Libert, O. Acta endocr. 41, 336–350 (1962).
Schally, A. V., Steelman, S. L. & Bowers, C. Y. Proc. Soc. exp. Biol. Med. 119, 208–212 (1965).
Deuben, R. R. & Meites, J. Endocrinology 74, 408–414 (1964).
Vale, W. W. & Rivier, J. E. Abstr. 6th int. Congr. Endocrinology (1980).
Villarreal, J. et al. Biochem. biophys. Res. Commun. 70, 551–558 (1976).
Schally, A. V., Baba, Y., Nair, R. M. G. & Bennett, C. D. J. biol. Chem. 246, 6647–6653 (1971).
Yudaev, N. E., Utescheva, Z. F., Norikova, T. E., Schvachkin, Y. P. & Smirnova, A. P. Dokl. Akad. Nauk SSSR 210, 212–215 (1973).
Brazeau, P., Böhlen, P. & Guillemin, R. Endocrinology (Abstr.) 110, 538 (1982).
Buckingham, J. C. in Progress in Medicinal Chemistry (eds Ellis, G. P. & West, G. P.) 166–210 (Elsevier, Amsterdam, 1978).
Vale, W., Rivier, C. & Brown, M. A. Rev. Physiol. 29, 473–527 (1977).
Frohman, L. A., Szabo, M., Berelowitz, M. & Stachura, M. A. J. clin. Invest. 65, 43–54 (1980).
Leveston, S. A. et al. J. clin. Endocr. Metab. 53, 682–689 (1981).
Böhlen, P., Thorner, M., Cronin, M., Shively, J. & Scheithauer, B. Endocrinology (Abstr.) 110, 540 (1982).
Thorner, M. O. et al. J. clin. Invest. (in the press).
Tatemoto, K. & Mutt, V. Proc. natn. Acad. Sci. U.S.A. 78, 6603–6607 (1981).
Vale, W., Grant, G., Amoss, M., Blackwell, R. & Guillemin, R. Endocrinology 91, 562–572 (1972).
Wittmann-Liebold, B. in Polypeptide Hormones (eds. Beers, R. F. Jr & Bassett, E. G.) 87–120 (Raven, New York, 1980).
Spiess, J., Rivier, J., Thorner, M. O. & Vale, W. Biochemistry (in the press).
Merrifield, R. B. J. Am. Chem. Soc. 85, 2149–2156 (1963).
Märki, W., Spiess, J., Taché, Y., Brown, M. & Rivier, J. E. J. Am. chem. Soc. 103, 3178–3185 (1981).
Rivier, J. J. Am. chem. Soc. 96, 2986–2992 (1974).
Vale, W., Spiess, J., Rivier, C. & Rivier, J. Science 213, 1394–1397 (1981).
Imura, H. Clinics Endocr. Metab. 9, 235–260 (1980).
Vale, W., Vaughan, J., Yamamoto, G., Spiess, J. & Rivier, J. Endocrinology (submitted).
Szabo, M., Chu, L. & Frohman, L. Endrocinology 111, 1235–1242 (1982).
Cronin, M. J., Rogol, A. D. & Thorner, M. O. J. clin. Endocr. Metab. 55, 381–383 (1982).
Cass, L. T. & Martin, J. B. Endrocrinology 108, 1869–1873 (1981).
Rivier, J. J. Liquid Chromatogr. 1, 343–367 (1978).
Spiess, J., Rivier, J., Rivier, C. & Vale, W. in Methods in Protein Sequence Analysis (ed. Elzinga, M.) 131–138 (Humana, New York, 1982).
Spiess, J., Rivier, J., Rivier, C. & Vale, W. Proc. natn. Acad. Sci. U.S.A. 78, 6517–6521 (1981).
Spiess, J., Rivier, J., Thorner, M. & Vale, W. Hormones and Cell Regulation (eds Dumont, J. & Nunez, J.) (Elsevier, Amsterdam, in the press).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rivier, J., Spiess, J., Thorner, M. et al. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature 300, 276–278 (1982). https://doi.org/10.1038/300276a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/300276a0
This article is cited by
-
Protective effects of GHRH antagonists against hydrogen peroxide-induced lung endothelial barrier disruption
Endocrine (2022)
-
Growth hormone — past, present and future
Nature Reviews Endocrinology (2018)
-
Ectopic acromegaly due to growth hormone releasing hormone
Endocrine (2013)
-
Ectopic growth hormone-releasing hormone secretion by a bronchial carcinoid tumor: clinical experience following tumor resection and long-acting octreotide therapy
Pituitary (2012)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.